How Eli Lilly Is Making Insulin More Affordable

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
How Eli Lilly Is Making Insulin More Affordable

© 6okean / Getty Images

Drug companies have been decried in the United States for high prices, but Eli Lilly and Co. (NYSE: LLY | LLY Price Prediction) is looking to fight this trend — at least a little. The pharmaceutical giant has announced that its Insulin Lispro Injection is now available for order in pharmacies for people who use Eli Lilly’s rapid-acting insulin and need a lower-cost option.

Now, Eli Lilly’s Insulin Lispro Injection has a 50% lower list price than identical medicine Humalog U-100 and is available in both a vial and KwikPen. Because they are the same insulin, pharmacists will be able to substitute Insulin Lispro Injection for Humalog.

Back in March, Eli Lilly announced plans to introduce Insulin Lispro Injection, which fills another gap in the health care system. The people who are most likely to benefit from Insulin Lispro Injection are Medicare Part D beneficiaries, people with high-deductible health plans and the uninsured who use Humalog.

Currently, about 95% of people in the United States pay $95 or less a month for their Humalog prescription, and 43% pay $0 at the retail pharmacy. With the launch of Insulin Lispro Injection, even more people will pay lower amounts at the pharmacy.

[nativounit]

Mike Mason, senior vice president, Connected Care and Insulins, commented:

The current healthcare system isn’t working for everyone, causing a growing number of people with chronic conditions to struggle to afford their medicine. But even one person with diabetes who can’t afford insulin is too many, which is why we introduced Insulin Lispro Injection. It adds to our suite of solutions that help significantly lower the amount people pay until a more sustainable solution is achieved.

Will this move help Eli Lilly escape the list of America’s most hated companies? In addition, check out 10 things to consider before buying an insulin pen.

Shares of Eli Lilly were last seen at $116.85, in a 52-week range of $81.61 to $132.13. The consensus price target is $124.57.

[recirclink id=549064]
[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618